key: cord-0801761-i7vrv2wd
authors: Tan, Hyon-Xhi; Juno, Jennifer A; Lee, Wen Shi; Barber-Axthelm, Isaac; Kelly, Hannah G; Wragg, Kathleen M; Esterbauer, Robyn; Amarasena, Thakshila; Mordant, Francesca L; Subbarao, Kanta; Kent, Stephen J; Wheatley, Adam K
title: Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques
date: 2020-09-02
journal: bioRxiv
DOI: 10.1101/2020.09.01.278630
sha: 57786d13067f8033c30afd30e0ee989bb1908f49
doc_id: 801761
cord_uid: i7vrv2wd

SARS-CoV-2 vaccines are advancing into human clinical trials, with emphasis on eliciting high titres of neutralising antibodies against the viral spike (S). However, the merits of broadly targeting S versus focusing antibody onto the smaller receptor binding domain (RBD) are unclear. Here we assessed prototypic S and RBD subunit vaccines in homologous or heterologous prime-boost regimens in mice and non-human primates. We find S is highly immunogenic in mice, while the comparatively poor immunogenicity of RBD was associated with limiting germinal centre and T follicular helper cell activity. Boosting S-primed mice with either S or RBD significantly augmented neutralising titres, with RBD-focussing driving moderate improvement in serum neutralisation. In contrast, both S and RBD vaccines were comparably immunogenic in macaques, eliciting serological neutralising activity that generally exceed levels in convalescent humans. These studies confirm recombinant S proteins as promising vaccine candidates and highlight multiple pathways to achieving potent serological neutralisation.

SARS-CoV-2 vaccines are advancing into human clinical trials, with emphasis on 28 eliciting high titres of neutralising antibodies against the viral spike (S). However, the 29 merits of broadly targeting S versus focusing antibody onto the smaller receptor 30 binding domain (RBD) are unclear. Here we assessed prototypic S and RBD subunit 31 vaccines in homologous or heterologous prime-boost regimens in mice and non-32 human primates. We find S is highly immunogenic in mice, while the comparatively 33 polypeptide and cleaved into S1 and S2 subunits, with a hetero-trimeric quaternary 53 structure common to many respiratory viruses (reviewed in Li, 2016) . Cell entry is 54 mediated by engagement of the enzyme ACE2 on the target cell surface by the viral 55

Consistent with GC B cell frequencies, immunisation with S induced high frequencies 119 of T follicular helper (TFH) cells (CXCR5 ++ BCL-6 + ; median 0.7%; 0.3-1.1) relative 120 to OVA (median 0.4%; 0.2-0.8) or RBD (median 0.13%, 0.1-0.2) ( Figure 1E ; gating 121 Figure S2 ). The median fluorescent intensity (MFI) of BCL-6 expression in TFH was 122 notably higher in S-vaccinated animals (median 5303 for S, 4756 for OVA and 4353 123 for RBD) ( Figure 1E ). Analysis of TFH specificity using an activation induced 124 marker (AIM) assay (Jiang et al., 2019 ) and pools of RBD or non-RBD S overlapping 125 peptides indicated that the TFH response is dominated by non-RBD-localised epitopes 126 in S-immunised animals ( Figure 1F ). Further, RBD peptides elicited weak CD154 127 responses upon re-stimulation in comparison to non-RBD peptides ( Figure 1F ). 128

Epitope mapping of peptides spanning the RBD indicated that only 3 RBD-derived 129 peptides were recognised by CD4 T cells in C57BL/6 mice ( Figure S3 ), one of which 130 was substantially more immunogenic than the others (P99, sequence 131 TNVYADSFVIRGDEV). In contrast, a more extensive number (>8) of S epitopes 132 were identified outside the RBD (4 of which are shown in Figure S3 ). In S-vaccinated 133 animals, the 3 RBD-derived epitopes were subdominant to the most immunogenic 134 non-RBD S epitopes and relatively poor inducers of CD154 expression ( Figure S3 highlights additional antibody targets for vaccine protection. To assess the relative 154 merits of RBD-focussed antibody responses versus more holistically targeting the 155 entire S, we primed C57BL/6 mice with S or RBD, and then boosted 21 days later 156 with either homologous or heterologous immunogens. Homologous S prime-boost (S-157 S) elicited high reciprocal serum endpoint titres of both S-(median 2.77 x 10 6 ; IQR 158 1.71-3.62) and RBD-specific antibodies (2.28 x 10 6 ; IQR 1.23-3.17) (Figure 2A ). In 159 contrast to a single RBD dose, we found that homologous RBD prime-boost (R-R) 160 immunisation was capable of eliciting modest serum titres of S-and RBD-specific 161 antibodies. RBD prime-S boost (R-S) induced similarly modest titres. However, we 162 find RBD boosting of S-primed animals (S-R) markedly increased RBD-specific 163 serum antibody titres 4.2-fold relative to S-S (p=0.0055). Inhibition of ACE2-RBD 164 interaction by serum antibodies was similarly enhanced in the S-R group compared to 165 the S-S group ( Figure 2B , Figure S5 ). Selective RBD focussing translated into 166 increased serum neutralisation, with S-R eliciting 2.5-fold higher activity (median 167 361; IQR 226-706) compared to S-S (143; IQR 96-254) (p=0.0055) ( Figure 2C ). 168

Neither R-R nor R-S immunisation reliably induced significant serum neutralising 169 activity, although they elicited modest levels of antibodies that block ACE2-RBD 170 engagement. The capacity of S-S and S-R immunisation to elicit potent binding and 171 neutralising responses in C57BL/6 mice was mirrored in BALB/c mice ( Figure S6 ). 172

The profile of B and T cell immunity was assessed in draining lymph nodes 2 weeks 174 after the boost immunisation. R-R elicited the lowest GC B cell responses measured 175 using BCL-6 + (0.5%; IQR 0.4-1.2) or surface GL7 + (22.3%; IQR 20.5-31.6) 176 expression ( Figure 2D ). Both S-S (BCL- showed robust GC induction (BCL-6 + : 3.0%; IQR 2.3-3.2) (GL7 + : 54.2%; IQR 45.9-180 57.6), likely reflecting a primary response against non-RBD epitopes within S. The 181 hierarchy of GC activity was mirrored in the frequency of probe-specific GC B cells, 182 with R-S (19.5% (IQR:14.7-21.8) and S-S (10.6%; IQR 9.46-14.4) eliciting high 183 frequencies of S-specific GC B cells ( Figure 2E ), while low frequencies were 184 observed for R-R (1.83%; IQR 1.25-2.98) and S-R groups (2.9%; IQR 2.21-4.96). 185 RBD-specific GC B cells were highest in R-R (8.07%; IQR 3.58-11.9) and S-R 186 (6.79%; IQR 5.65-14.2) groups, with lower frequencies after S-S (2.86%; 0.96-187 7.11%) and R-S regimens (1.20%; IQR 0.67-2.62). GC TFH frequencies were highest 188 in R-S animals (0.69%, IQR 0.6-1.1) compared to the other groups (R-R 0.4%, IQR S8A) were elicited in all animals, with S-S (23.4%, range 18.5-28.7) and S-R (22.6%, 218 range 7.5-27.8) immunised animals displaying higher GC frequencies relative to R-R 219 (12.6%, range 7.86-17.4) immunised animals. GC B cell specificity was also assessed 220 by S-or RBD-probe binding ( Figure 3E ). RBD-specific B cells were detected in all 221 groups, with R-R immunised animals displaying the highest levels (22.7%, range 222 22.3-23.1) followed by the S-R (9.02%, range 7.73-11.4) and S-S (3.88%, range 2.03-223 4.43) groups. In contrast, high frequencies of S-specific GC B cells were elicited in S-224 S (4.81%, range 3.41-7.71) and S-R (9.11%, range 0.82-13.6) immunised, but not R-R 225 immunised animals. 226 227 GC TFH (CD3 + CD4 + CXCR5 ++ PD-1 ++ ; gating in Figure S9A ) were also detected in 228 all draining lymph nodes (11.4% of total LN CD4 + T cells), with a median of 13% 229 exhibiting recent proliferation as measured by Ki-67 expression ( Figure 3F ). S-230 specific TFH targeting either non-RBD or RBD peptides were detected in all animals; 231 interestingly, RBD-derived peptides tended to be more frequently recognised by GC 232 TFH than non-RBD epitopes (2.4% non-RBD, S-specific versus 6.2% RBD-specific; 233 

While our results suggest that adjuvanted protein vaccines are reliably immunogenic 255 in mice and non-human primates, it remains unclear how well these models 256 recapitulate human immunity to SARS-CoV-2. As a reference, S-and RBD-specific 257 antibody and serum neutralisation titres were assessed in a panel of 72 convalescent 258 donors recovered from COVID-19 (participant details in Table 1 ). We find that both 259 S-S and S-R immunised mice display high comparative titres, with potent serum 260 neutralisation appearing upon boosting with SARS-CoV-2 immunogens ( Figure 4) . 

The authors declare no competing interests. 363 and read at 450nm. Endpoint titres were calculated as the reciprocal serum dilution 559 giving signal 2x background using a fitted curve (4 parameter log regression). 560

An ELISA to measure the ability of plasma antibodies to block interaction between 562 recombinant human ACE2 (kindly provided by Merlin Thomas) and SARS-CoV-2 563 RBD was performed as previously described (Juno et al., 2020) . Briefly, 96-well 564

Maxisorp plates (Thermo Fisher) were coated overnight at 4ºC with 2.5µg/ml of 565 recombinant RBD protein in carbonate-bicarbonate coating buffer (Sigma). After 566 blocking with PBS containing 1% BSA, duplicate wells of serially diluted plasma 567

(1:25 to 1:102,400) were added and incubated for 1 hour at room temperature. Plates 568 were then incubated with 1µg/ml of biotinylated recombinant ACE2 protein for 1 569 hour at room temperature followed by incubation with HRP-conjugated streptavidin 570 

coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in 616

A neutralizing human antibody binds to the N-terminal 619 domain of the spike protein of SARS-CoV-2

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus 622 macaques

Circulating follicular T helper cells and cytokine 625 profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine

Safety and 629 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a 630 preliminary report of a phase 1/2, single-blind, randomised controlled trial. The 631

CoV2373 vaccine protects cynomolgus macaque upper and lower airways against 635 SARS-CoV-2 challenge

Efficacy of a bivalent 638 L1 virus-like particle vaccine in prevention of infection with human papillomavirus 639 types 16 and 18 in young women: a randomised controlled trial

Prophylaxis with a 643 middle east respiratory syndrome coronavirus (MERS-CoV)-specific human 644 monoclonal antibody protects rabbits from MERS-CoV infection

Dynamic changes in circulating T follicular helper cell composition predict 649

neutralising antibody responses after yellow fever vaccination

Rapid 653 decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19

An mRNA vaccine against SARS-CoV-2 -preliminary report

Identification of murine antigen-specific T follicular helper cells 660 using an activation-induced marker assay

Humoral and circulating 663 follicular helper T cell responses in recovered patients with COVID-19

First-in-human trial of a SARS-667

CoV-2 recombinant spike protein nanoparticle vaccine

Circulating TFH cells

serological memory, and tissue compartmentalization shape human influenza-specific 672 B cell immunity

Structure of the SARS-CoV-2 spike receptor-binding domain 675 bound to the ACE2 receptor

Structure, function, and evolution of coronavirus spike proteins

The impact of mutations in SARS-CoV-2 spike on viral infectivity 680 and antigenicity

Potent neutralizing antibodies against multiple 683 epitopes on SARS-CoV-2 spike

Clinical and immunological assessment of 686 asymptomatic SARS-CoV-2 infections

SARS-CoV-2 protein 689 subunit vaccination elicits potent neutralizing antibody responses

Targeted isolation 693 of antibodies directed against major sites of SIV Env vulnerability

Phase 1/2 study to 697 describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate 698 (BNT162b1) in adults 18 to 55 years of age: interim report

Cleavage strongly influences 702 whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like 703 conformation

Convergent 706 antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing 710 antibodies and protection from disease in a small animal model

Longitudinal evaluation and 714 decline of antibody responses in SARS-CoV-2 infection

Structure and 718 immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus 719 sequence

Prior infection and passive transfer of 722 neutralizing antibody prevent replication of severe acute respiratory syndrome 723 coronavirus in the respiratory tract of mice

Subdominance and poor 726 intrinsic immunogenicity limit humoral immunity targeting influenza HA stem

Cloning and expression of murine 729

Ig genes from single B cells

Immunologic 732 responses following administration of a vaccine targeting human papillomavirus 733

Types 6, 11, 16, and 18

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study

Site-742 specific glycan analysis of the SARS-CoV-2 spike

Immunogenicity and safety of a 745 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 746 years or older: a randomised, double-blind

Potently neutralizing and 750 protective human antibodies against SARS-CoV-2